Masked volume wise principal component analysis of small adrenocortical tumours in dynamic [11C]-metomidate positron emission tomography

BackgroundIn previous clinical Positron Emission Tomography (PET) studies novel approaches for application of Principal Component Analysis (PCA) on dynamic PET images such as Masked Volume Wise PCA (MVW-PCA) have been introduced. MVW-PCA was shown to be a feasible multivariate analysis technique, which, without modeling assumptions, could extract and separate organs and tissues with different kinetic behaviors into different principal components (MVW-PCs) and improve the image quality.MethodsIn this study, MVW-PCA was applied to 14 dynamic 11C-metomidate-PET (MTO-PET) examinations of 7 patients with small adrenocortical tumours. MTO-PET was performed before and 3 days after starting per oral cortisone treatment. The whole dataset, reconstructed by filtered back projection (FBP) 0–45 minutes after the tracer injection, was used to study the tracer pharmacokinetics.ResultsEarly, intermediate and late pharmacokinetic phases could be isolated in this manner. The MVW-PC1 images correlated well to the conventionally summed image data (15–45 minutes) but the image noise in the former was considerably lower. PET measurements performed by defining "hot spot" regions of interest (ROIs) comprising 4 contiguous pixels with the highest radioactivity concentration showed a trend towards higher SUVs when the ROIs were outlined in the MVW-PC1 component than in the summed images. Time activity curves derived from "50% cut-off" ROIs based on an isocontour function whereby the pixels with SUVs between 50 to 100% of the highest radioactivity concentration were delineated, showed a significant decrease of the SUVs in normal adrenal glands and in adrenocortical adenomas after cortisone treatment.ConclusionIn addition to the clear decrease in image noise and the improved contrast between different structures with MVW-PCA, the results indicate that the definition of ROIs may be more accurate and precise in MVW-PC1 images than in conventional summed images. This might improve the precision of PET measurements, for instance in therapy monitoring as well as for delineation of the tumour in radiation therapy planning.

[1]  M. Bergström,et al.  [11C]metomidate positron emission tomography of adrenocortical tumors in correlation with histopathological findings. , 2006, The Journal of clinical endocrinology and metabolism.

[2]  B. Ahrén,et al.  Adrenal incidentaloma – experience of a standardized diagnostic programme in the Swedish prospective study , 2002, Journal of internal medicine.

[3]  Habib Zaidi,et al.  Strategies for attenuation compensation in neurological PET studies , 2007, NeuroImage.

[4]  Ewert Bengtsson,et al.  Non-isotropic noise correlation in PET data reconstructed by FBP but not by OSEM demonstrated using auto-correlation function , 2005, BMC Medical Imaging.

[5]  R. Boellaard,et al.  Effects of noise, image resolution, and ROI definition on the accuracy of standard uptake values: a simulation study. , 2004, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[6]  G. Braunstein,et al.  Management of the Clinically Inapparent Adrenal Mass (Incidentaloma) , 2003, Annals of Internal Medicine.

[7]  W. Wadsak,et al.  Positron emission tomography imaging of adrenal masses: 18F-fluorodeoxyglucose and the 11β-hydroxylase tracer 11C-metomidate , 2004, European Journal of Nuclear Medicine and Molecular Imaging.

[8]  Rhonda A. Brownbill,et al.  Measuring body composition in overweight individuals by dual energy x-ray absorptiometry , 2005, BMC Medical Imaging.

[9]  A. Sundin,et al.  Computed tomography, magnetic resonance imaging and 11C-metomidate positron emission tomography for evaluation of adrenal incidentalomas. , 2009, European journal of radiology.

[10]  Stefan R Bornstein,et al.  The clinically inapparent adrenal mass: update in diagnosis and management. , 2004, Endocrine reviews.

[11]  H. Malcolm Hudson,et al.  Accelerated image reconstruction using ordered subsets of projection data , 1994, IEEE Trans. Medical Imaging.

[12]  J. Rastad,et al.  PET imaging of adrenal cortical tumors with the 11beta-hydroxylase tracer 11C-metomidate. , 2000, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[13]  G. Braunstein.  Management of the Clinically Inapparent Adrenal Mass , 2004 .

[14]  W. Young,et al.  Increased diagnosis of primary aldosteronism, including surgically correctable forms, in centers from five continents. , 2004, The Journal of clinical endocrinology and metabolism.

[15]  D. Ross,et al.  Incidentally discovered adrenal masses. , 1989, American journal of surgery.

[16]  H. Kirchner,et al.  Monitoring of a new approach of immunotherapy with allogenic 111In-labelled NK cells in patients with renal cell carcinoma , 2004, European Journal of Nuclear Medicine and Molecular Imaging.

[17]  J. Axelsson,et al.  Volume-Wise Application of Principal Component Analysis on Masked Dynamic PET Data in Sinogram Domain , 2006, IEEE Transactions on Nuclear Science.

[18]  Ewert Bengtsson,et al.  Noise correlation in PET, CT, SPECT and PET/CT data evaluated using autocorrelation function: a phantom study on data, reconstructed using FBP and OSEM , 2005, BMC Medical Imaging.

[19]  George Kontaxakis,et al.  Analysis and interpretation of dynamic FDG PET oncological studies using data reduction techniques , 2007, Biomedical engineering online.

[20]  J. Rastad,et al.  PET and parathyroid L-[carbon-11]methionine accumulation in hyperparathyroidism. , 1996, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[21]  J. Lau,et al.  Management of clinically inapparent adrenal mass. , 2002, Evidence report/technology assessment.

[22]  K. Någren,et al.  Imaging of adrenal incidentalomas with PET using (11)C-metomidate and (18)F-FDG. , 2004, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[23]  NIH state-of-the-science statement on management of the clinically inapparent adrenal mass ("incidentaloma"). , 2002, NIH consensus and state-of-the-science statements.

[24]  Ewert Bengtsson,et al.  A new application of pre-normalized principal component analysis for improvement of image quality and clinical diagnosis in human brain PET studies—Clinical brain studies using [11C]-GR205171, [11C]-l-deuterium-deprenyl, [11C]-5-Hydroxy-l-Tryptophan, [11C]-l-DOPA and Pittsburgh Compound-B , 2006, NeuroImage.